Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials
Mann JFE, Hansen T, Idorn T, et al
Lancet Diabetes Endocrinol. 2020;S2213-8587(20)30313-2
Leggi


